LIVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LivaNova PLC (LIVN) does not present a compelling buy opportunity for a beginner investor with a long-term focus at this time. While the company has shown revenue growth and received positive analyst updates, the financial performance is mixed, with significant declines in net income, EPS, and gross margin. Additionally, technical indicators do not strongly support a bullish trend, and there are no significant catalysts or trading signals to justify immediate action.
The MACD is positive and expanding, indicating a potential bullish momentum. RSI is neutral at 56.911, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 64.363), which could limit upside potential in the short term.
Analysts have raised price targets recently, citing strong revenue growth and a solid 2026 outlook. The company's strategic focus on innovation and clinical data generation is viewed positively.
There are no recent news catalysts or significant trading trends from hedge funds or insiders. The stock's short-term trend suggests limited upside potential.
In Q4 2025, revenue increased by 12.15% YoY to $360.92M. However, net income dropped by 44.70% YoY to $30.91M, EPS fell by 44.12% YoY to $0.57, and gross margin declined by 2.54% YoY to 66.43%.
Analysts have raised price targets, with the highest being $85 (Mizuho) and the lowest being $73 (Barclays and Goldman Sachs). Ratings range from Neutral to Outperform, with a generally positive outlook on the company's medium-term growth potential.
